title: [Clinical evaluation of monotherapy with ceftazidime for severe infections complicating hematological disorders. Hyogo Cooperative Study Group of Infectious Diseases Complicating Hematological Disorders].
abstract: Clinical effects of the monotherapy with ceftazidime (CAZ) were evaluated in patients with severe infections associated with febrile granulocytopenia in hematological disorders in 10 institutions. CAZ (4-6g/day) was administered intravenously by drip infusion divided into 2 to 4 doses. 83% of the underlying diseases were hematological malignancies. Infections mainly consisted of documented sepsis (10%), presumed sepsis (60%). Overall efficacy rate was 65%, and that of septic patients was 83.3%. Adverse reactions were minimal, and this study revealed safety of CAZ.
authors.forename: Y
authors.initials: Y
authors.lastname: Takemoto
authors.forename: A
authors.initials: A
authors.lastname: Kanamaru
authors.forename: K
authors.initials: K
authors.lastname: Nagai
authors.forename: H
authors.initials: H
authors.lastname: Hara
authors.forename: S
authors.initials: S
authors.lastname: Nakayama
authors.forename: S
authors.initials: S
authors.lastname: Himei
authors.forename: T
authors.initials: T
authors.lastname: Ikeda
authors.forename: N
authors.initials: N
authors.lastname: Iwao
authors.forename: H
authors.initials: H
authors.lastname: Tago
authors.forename: N
authors.initials: N
authors.lastname: Yamaguchi
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001424:Bacterial Infections / Q000188:drug therapy*; D002442:Ceftazidime / Q000627:therapeutic use*; D002648:Child; D005260:Female; D006402:Hematologic Diseases / Q000150:complications*; D006801:Humans; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged
chemical_list: D002442:Ceftazidime